WINT - Windtree completes enrollment in phase 2 trial of lucinactant for COVID-19 lung injury

Windtree Therapeutics (WINT) completed enrollment in its phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is expected in Q1. The trial enrolled 20 patients to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in patients who are mechanically ventilated as a result of COVID-19 associated acute lung injury. Functional changes in gas exchange and lung compliance are also being measured.

For further details see:

Windtree completes enrollment in phase 2 trial of lucinactant for COVID-19 lung injury